Are peptides legal in the Dominican Republic?

The Dominican legal framework

In the Dominican Republic, health-related products are governed by the General Health Law 42-01 and the Medicines Regulation 246-06, administered by DIGEMAPS (the national directorate for medicines, food and health products). DIGEMAPS registers medicines, oversees their sale and authorizes imports. There is currently no Dominican rule that treats "research peptides" as their own category — legality depends on how each product is classified and what it is sold for.

Category matters more than molecule

The same peptide can exist in several categories with different rules:

1 · Registered medicines. Example: brand semaglutide registered with DIGEMAPS is dispensed like any medicine — with a prescription. 2 · Unregistered medicines. Non-registered brands can only enter under per-patient special authorization (a pathway in Law 42-01) with a specialist prescription. 3 · Cosmetics. Topical peptides (e.g., cosmetic GHK-Cu) are notified under Decree 125-22. 4 · Research reagents (RUO). Compounds sold as reference materials for research: they are not registered medicines, are not approved by DIGEMAPS for human use, and are not sold for consumption. This is the category Renova — and most of the international research-peptide market — operates in.

What "research use only" means in practice

A serious RUO supplier labels every product as not for human or veterinary consumption; makes no medical claims ("cures", "treats", "slims"); gives no clinical usage instructions; requires legal age; and documents identity and purity with third-party testing. That framework doesn't turn the product into a medicine — it deliberately keeps it outside that category. If a seller promises therapeutic effects, they are doing exactly what every country's regulation prohibits.

The U.S. regulatory signal (2026)

In July 2026 the FDA's compounding advisory committee (PCAC) evaluated 7 peptides for the 503A bulks list and backed 6: BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon (DSIP did not pass). The vote is advisory: it feeds an 8–12 month rulemaking process and legalizes nothing by itself — but it marks the direction of the regulatory conversation about these compounds in the region.

How to evaluate a supplier in the DR (checklist)

In a market with no specific category, diligence is on you. Six verifiable things that separate a serious supplier: (1) a public COA per compound, linkable and verifiable with the lab (third-party HPLC + mass spectrometry, not "internal testing"); (2) honest wording — "follows cGMP guidelines", not certifications it can't demonstrate; (3) documented cold chain for reconstituted compounds; (4) published prices, minimum order and shipping policy; (5) replacement guarantee for damage; (6) explicit RUO disclaimers site-wide. At Renova all six are published: certificates at /coa/, the full process at /our-process/.

Sources

DIGEMAPS · Law 42-01 · Regulation 246-06 · FDA PCAC Jul-2026